Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece

• Váldodahkkit: George Gourzoulidis (Dahkki), Myrto Barmpouni (Dahkki), Vasiliki Kossyvaki (Dahkki), Jeffrey Vietri (Dahkki), Charalampos Tzanetakos (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2023-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

ObjectiveHigher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to...